RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data

Key Takeaways Shares of Rhythm Pharmaceuticals (RYTM) were up 36.6% yesterday after it reported positive top-line data from a phase II study evaluating the investigational oral melanocortin-4 receptor (MC4R) agonist, bivamelagon (formerly LB54640), in patients with acquired hypothalamic obesity. Acquired hypothalamic obesity is a severe and debilitating condition caused by hypothalamic damage, often resulting from brain tumors, their treatment or other injuries. This leads to rapid weight gain, uncontrollab ...